Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.06
    -0.46 (-5.45%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novavax Inc (NVAX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Novavax (NVAX) to earn -$0.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $473.10M. Of 9 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 3 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 56% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy555.6%
    Hold111.1%
    Sell111.1%
    Strong Sell222.2%
    Consensus
    Hold
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 48.0%.

    Fiscal year ending Dec 31, 2026
    -$0.05
    EPS consensus, revenue $473.10M
    Fiscal year ending Dec 31, 2027
    -$0.45
    EPS consensus, revenue $246.08M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.05-$0.38 to $0.358$473.10M$407.60M to $580.41M8
    Dec 31, 2027-$0.45-$1.35 to $0.358$246.08M$160.00M to $338.98M8

    Quarterly Estimates

    The EPS consensus falls from $0.55 for the quarter ending Dec 31, 2026 to -$0.35 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.55$0.18 to $0.9810$222.64M$140.24M to $331.70M10
    Mar 31, 2027-$0.35-$0.45 to -$0.243$35.82M$28.45M to $43.20M2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202632
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.63.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.05-$0.52-$0.59-$0.63-$0.63N/A
    Fiscal year ending Dec 31, 2027-$0.45-$0.13-$0.08-$0.22-$0.22N/A
    Quarter ending Mar 31, 2027-$0.35-$0.32-$0.31-$0.31-$0.31N/A

    Frequently Asked Questions About NVAX

    What is the NVAX stock forecast?

    Consensus analyst estimates put Novavax's EPS at -$0.05 for the fiscal year ending Dec 31, 2026, on revenue of $473.10M. The consensus rating from 9 analysts is Hold.

    How do analysts rate NVAX stock?

    Of 9 analysts covering Novavax, 0 rate it Strong Buy, 5 Buy, 1 Hold, 1 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from NVAX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.05, with estimates from -$0.38 to $0.35 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.45, with estimates from -$1.35 to $0.35 from 8 analysts.

    What revenue do analysts expect from Novavax next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $473.10M, with estimates from $407.60M to $580.41M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $246.08M, with estimates from $160.00M to $338.98M.

    How many analysts cover NVAX?

    9 analysts rate Novavax stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.